Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Jump-Start Your Search For Promising Trade Ideas With Barchart Premier’s "Top Stock Pick". FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Menu

Lava Therapeutics N.V. (LVTX)

Lava Therapeutics N.V. (LVTX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Increasing Incidence of Pancreatic Cancer Leading to a $6.85 Billion Dollar Market Size for New Treatments FinancialNewsMedia - Tue Mar 5, 7:30AM CST

EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NASDAQ:OCEA),(NASDAQ:LVTX),(NYSE:MRK),(NYSE:ABBV) EQNX::TICKER_END

OCEA : 0.7129 (+3.32%)
ONCY : 0.9800 (-1.85%)
ONC.TO : 1.37 (-2.14%)
LVTX : 1.4800 (-2.63%)
MRK : 99.86 (+2.48%)
ABBV : 171.73 (+2.37%)
Increasing Incidence of Pancreatic Cancer Leading to a $6.85 Billion Dollar Market Size for New Treatments GlobeNewswire - Tue Mar 5, 7:30AM CST

ONCY : 0.9800 (-1.85%)
ONC.TO : 1.37 (-2.14%)
LVTX : 1.4800 (-2.63%)
MRK : 99.86 (+2.48%)
ABBV : 171.73 (+2.37%)
LAVA Therapeutics (NASDAQ: LVTX) Enters into Global Licensing Agreement with Seagen (NASDAQ: SGEN) to Develop and Commercialize LAVA-1223 Spotlight Growth - Mon Sep 26, 2022

LAVA Therapeutics N.V. (NASDAQ: LVTX) is engaged as a clinical-stage oncology company, which is focused on the research and development

LVTX : 1.4800 (-2.63%)
SGEN : 228.74 (-0.07%)
Seagen and LAVA Therapeutics Announce Exclusive Worldwide License Agreement to Advance LAVA-1223, a Preclinical Gamma Delta Bispecific T Cell Engager for EGFR-Expressing Solid Tumors Business Wire - Mon Sep 26, 2022

Seagen Inc. (Nasdaq: SGEN), a world leader and pioneer in antibody-drug conjugate (ADC) therapies, and LAVA Therapeutics N.V. (Nasdaq: LVTX), a clinical-stage immuno-oncology company focused on developing...

SGEN : 228.74 (-0.07%)
LVTX : 1.4800 (-2.63%)
LAVA Therapeutics Highlights Encouraging Clinical Updates on Lead Program, LAVA-051, in Chronic Lymphocytic Leukemia and Multiple Myeloma Patients Globe Newswire - Thu Jun 16, 2022

Clinical update call featuring LAVA-051 investigator Dr. Arnon Kater and Company management summarized initial Phase 1/2a clinical trial data presented at...

LVTX : 1.4800 (-2.63%)
LAVA Therapeutics Announces Two Appointments to its Board of Directors Globe Newswire - Wed Jun 15, 2022

James Noble and Jay Backstrom, M.D, M.P.H, bring vast global leadership experiences at public biopharmaceutical companies...

LVTX : 1.4800 (-2.63%)
LAVA Therapeutics to Present Initial Phase 1/2a Clinical Trial Dose Escalation Data of LAVA-051 in Chronic Lymphocytic Leukemia and Multiple Myeloma Patients at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting Globe Newswire - Wed Jun 1, 2022

LAVA Therapeutics to host clinical results conference call and webcast on June 16 at 8:00 a.m. EDT/2:00 p.m. ...

LVTX : 1.4800 (-2.63%)
LAVA Therapeutics Announces Annual Meeting of Shareholders Globe Newswire - Tue May 31, 2022

UTRECHT, The Netherlands and PHILADELPHIA, May 31, 2022 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (Nasdaq: LVTX) (LAVA), a clinical stage...

LVTX : 1.4800 (-2.63%)
LAVA Therapeutics Provides Business Update and Reports First Quarter Financial Results Globe Newswire - Tue May 17, 2022

LAVA-051 updated interim clinical data from Phase 1/2a clinical trial in patients with relapsed or refractory chronic lymphocytic leukemia and multiple...

LVTX : 1.4800 (-2.63%)
LAVA Therapeutics to Participate at the UBS Global Healthcare Conference Globe Newswire - Thu May 5, 2022

UTRECHT, The Netherlands and PHILADELPHIA, May 05, 2022 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (Nasdaq: LVTX), an immuno-oncology company focused on...

LVTX : 1.4800 (-2.63%)

Barchart Exclusives

1 AI Stock to Buy and Hold for Long-Term Growth Barchart - Thu Nov 21, 7:18PM CST
Pure Storage stands out in AI data storage, bolstered by a new partnership with CoreWeave and a solid financial track record, making it an intriguing stock for AI-focused investors Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar

[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot